Search results | viral

Reports

Viral Partnering Terms and Agreements

The Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Stocks of smallpox anti-virals sore with $2.8bn supply contract

US Department of Health and Human Services (HHS) has awarded a contract to SIGA Technologies for 1.7 million courses of smallpox antivirals to combat bio-warfare pathogens.

Extension Denied: Gilead Sciences’ SPC Application for Combination Anti-Retrovirals

By Jonathan Ball and Camilla Sell, DMH Stallard, London The UK Intellectual Property Office (‘UKIP’) Hearing Officer’s recent decision in case BL O/006/08 (Re Gilead Sciences, Inc. 10 January 2008) has highlighted the difficulty faced by a pharmaceutical patentee seeking a Supplementary Protection Certificate (‘SPC’) for a commercially valuable combination product, relying on its basic more »

Aspen Pharmacare – Africa’s biggest generic drugmaker

Aspen Pharmacare specialises in the production of branded and generic pharmaceuticals and is currently the biggest pharmaceutical company in South Africa taking a 15% share of the total market.

Life Science M&A Deal Trends in Q2, 2014

By Steve Poile                                     With 110 deals announced, the second quarter continued on from the strong start for life science M&A during 2014.

Bavarian Nordic: Biotechnology partnering activity 2009-2014

Bavarian Nordic is an international biotechnology headquartered in Denmark.

Bavarian Nordic: Biotechnology smallpox fighters

Bavarian Nordic is a biotechnology company developing and manufacturing therapeutics for cancer and infectious diseases.

Industry trends in infectious vaccines dealmaking – 2009 to 2014

Industry trends suggest that infectious vaccines research and development is an increasingly active component of healthcare business development. The last decade has witnessed a significant number of infectious vaccines partnering and M&A activity

Ranbaxy

Ranbaxy Laboratories is a top pharmaceutical company based in Haryana, India

Cancer vaccine

A cancer vaccine is a vaccine that treats existing cancer or prevents the development…

Novartis

Novartis is a top pharmaceutical company based in Basel, Switzerland

Events

Sorry, your search returned no results.


Deals

Merck licenses Moderna’s RNA-based antiviral vaccines and passive immunity therapies

Moderna Therapeutics announced a license and collaboration agreement with Merck for the discovery and development of vaccines and passive immunity treatments against viral diseases

Viralytics raises $27.1 million in public offering financing

Viralytics is undertaking a transformational capital raising of up to $27.1 million that is anticipated to fully fund the company in financing to the end of 2016 including the completion of its key CAVATAK clinical trials.

GlaxoSmithKline big pharma partners Immunocore for oncology and viral disease treatment

Immunocore Limited has entered into a partnership with pharma partners GlaxoSmithKline for multiple novel targets not addressable using antibody-based technologies.

Genentech pharma delas Immunocore for $330 million cancer and viral targets

Immunocore has entered into pharma deals involving a collaborative R&D and licensing agreement with Genentech for the discovery and development of multiple novel cancer targets using Immunocore’s ImmTAC technology.

Boehringer Ingelheim pharma partners with Presidio for antiviral therapy

Presidio Pharmaceuticals pharma partners with Boehringer Ingelheim, a top big pharma company,in a non-exclusive collaboration for a Phase IIa clinical trial of an interferon-free, all-oral, direct-acting antiviral combination treatment for patients with chronic hepatitis C virus infection.

Big pharma Mylan announces supply of antiretroviral drugs to NACO in India

Mylan, a top big pharma announced that its India-based subsidiary Mylan Laboratories Limited has been selected as a leading supplier of antiretroviral drugs to India’s National AIDS Control Organization .

Gilead Sciences collaborates with Indian pharma partners for antiretroviral therapy

Gilead Sciences, together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into a pharma partners agreements to collaborate on promoting access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries – including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.

Bristol-Myers Squibb in Mutli Year strategic pharma alliances deal with Prosetta Antiviral

Prosetta Antiviral announced the execution of a strategic pharma alliances agreement with Bristol-Myers Squibb. a big pharma company to further discover and develop select drug candidates representing new, novel classes of antiviral drugs.

SIGA gets nod for $2.8bn antiviral contract, shares rocket up

SIGA Technologies says it has been selected to deliver a smallpox antiviral drug to the nation’s biodefense stockpile, landing a contract which is worth $500 million at the base level and zooms all the way up to $2.8 billion if HHS’s Biomedical Advanced Research and Development Authority picks up all the options. The agency intends more »

Ark Therapeutics signs preferred supplier memorandum with Merck to manufacture adenoviral medicines

The appointment as preferred manufacturing supplier is subject to the signing of a binding detailed manufacturing agreement.